Healthcare provider profile · identity verified

Cathrine J Wheeler, MD

Internal Medicine · SEATTLE, WA · NPI 1316096597

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	400	111
Levothyroxine Sodium	Levothyroxine Sodium	231	63
Amlodipine Besylate	Amlodipine Besylate	198	51
Lisinopril	Lisinopril	122	34
Gabapentin	Gabapentin	107	26
Losartan Potassium	Losartan Potassium	106	32
Sertraline Hcl	Sertraline Hcl	101	26
Metoprolol Succinate	Metoprolol Succinate	91	26
Hydrochlorothiazide	Hydrochlorothiazide	80	24
Omeprazole	Omeprazole	80	25
Alendronate Sodium	Alendronate Sodium	73	19
Valsartan	Valsartan	72	19
Escitalopram Oxalate	Escitalopram Oxalate	71	17
Rosuvastatin Calcium	Rosuvastatin Calcium	63	16
Metformin Hcl Er	Metformin Hcl	62	18
Famotidine	Famotidine	57	suppressed
Pravastatin Sodium	Pravastatin Sodium	57	17
Eliquis	Apixaban	53	15
Carvedilol	Carvedilol	50	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	48	15
Chlorthalidone	Chlorthalidone	39	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	suppressed
Potassium Chloride	Potassium Chloride	36	suppressed
Simvastatin	Simvastatin	36	11
Trazodone Hcl	Trazodone Hcl	35	12
Metformin Hcl	Metformin Hcl	34	11
Ozempic	Semaglutide	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Synthroid	Levothyroxine Sodium	29	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	28	19
Bupropion Xl	Bupropion Hcl	28	suppressed
Furosemide	Furosemide	28	suppressed
Telmisartan	Telmisartan	28	suppressed
Allopurinol	Allopurinol	27	suppressed
Celecoxib	Celecoxib	27	suppressed
Estradiol	Estradiol	25	11
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Jardiance	Empagliflozin	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	20	suppressed
Prednisone	Prednisone	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	12
Montelukast Sodium	Montelukast Sodium	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	11
Acyclovir	Acyclovir	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Bupropion Hcl	Bupropion Hcl	16	suppressed
Diazepam	Diazepam	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Alprazolam	Alprazolam	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Galantamine Hbr	Galantamine Hbr	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Atenolol	Atenolol	12	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Rivastigmine	Rivastigmine	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error